Sign In
Buy COGT
$32.26
-0.500 (-1.53%)
At Close: Jun 03, 2026
Ensign Peak Advisors Inc Grows Position in Cogent Biosciences, Inc. $COGT
04:46am, Monday, 01'st Dec 2025
Ensign Peak Advisors Inc grew its position in shares of Cogent Biosciences, Inc. (NASDAQ: COGT) by 162.0% in the undefined quarter, according to the company in its most recent filing with the Securiti
COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know
12:41pm, Thursday, 20'th Nov 2025
Cogent Biosciences soars as its bezuclastinib combo delivers strong phase III GIST results, driving momentum toward key regulatory filings.
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference
08:00am, Friday, 14'th Nov 2025
WALTHAM, Mass. and BOULDER, Colo., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined
Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031
11:16pm, Tuesday, 11'th Nov 2025
WALTHAM, Mass. and BOULDER, Colo., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (“Cogent”) (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genet
Cogent Biosciences: Soaring On Blowout GIST Data - I Expect More Upside
10:34am, Tuesday, 11'th Nov 2025
Cogent Biosciences, Inc. soared 120% after positive Phase 3 PEAK study results for bezuclastinib in imatinib-resistant GIST patients. COGT's bezuclastinib showed a 50% reduction in disease progression
Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock
04:01pm, Monday, 10'th Nov 2025
WALTHAM, Mass. and BOULDER, Colo.
Cogent: Another Win For Bezuclastinib In GIST Warrants Continued Strong Buy
02:27pm, Monday, 10'th Nov 2025
Cogent Biosciences, Inc. earns a Strong Buy rating due to positive phase 3 PEAK results for bezuclastinib + Sunitinib in 2nd-line GIST. Company's combination therapy showed a significant mPFS improvem
Cogent Biosciences, Inc. ( COGT ) Discusses Positive Phase 3 PEAK Trial Results of Bezuclastinib in Gastrointestinal Stromal Tumors November 10, 2025 8:00 AM EST Company Participants Christi Waarich -
Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST)
07:00am, Monday, 10'th Nov 2025
16.5 months median progression free survival (mPFS) for bezuclastinib plus sunitinib compared to 9.2 months mPFS for sunitinib monotherapy (HR=0.50, CI: 0.39-0.65; p
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results
09:01am, Monday, 03'rd Nov 2025
Phase 3 PEAK results in 2 nd -line GIST patients expected in November; pivotal APEX results in AdvSM patients expected in December
Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting
09:00am, Monday, 03'rd Nov 2025
SUMMIT data for bezuclastinib in NonAdvSM selected for two oral presentations which will describe its best-in-class potential Novel JAK2 V617F mutant-selective inhibitor announced as Cogent's newest p
WALTHAM, Mass. and BOULDER, Colo., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically define
KLP Kapitalforvaltning AS Raises Position in Cogent Biosciences, Inc. $COGT
03:08am, Wednesday, 22'nd Oct 2025
KLP Kapitalforvaltning AS raised its holdings in Cogent Biosciences, Inc. (NASDAQ: COGT) by 67.3% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Com
Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib
08:32am, Monday, 20'th Oct 2025
Detailed results from bezuclastinib's positive SUMMIT trial evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis planned for presentation at upcoming scientific conference this
Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 29'th Sep 2025
WALTHAM, Mass. and BOULDER, Colo.
